ICER to postpone assessment of gene therapy for beta thalassemia

3 March 2020 - Due to delay in regulatory submission, ICER will reinitiate assessment at a future date — ...

Read more →

ICER posts draft scoping document for the assessment of treatments for haemophilia A

24 January 2020 - Document open to public comment until 13 February 2020. ...

Read more →

ICER posts draft scoping document for the assessment of treatments for beta thalassaemia

6 January 2020 - Document open to public comment until 27 January 2020. ...

Read more →

ICER to assess gene therapy for haemophilia A

3 January 2020 - Report will be subject of New England CEPAC meeting in August 2020; open Input now being accepted ...

Read more →

ICER to assess gene therapy for beta thalassaemia

5 December 2019 - Report will be subject of New England CEPAC meeting in July 2020; open Input now being accepted ...

Read more →

ICER issues statement regarding manufacturer's manipulation of data from animal testing of Zolgensma

7 August 2019 - Yesterday afternoon, the FDA announced that Novartis informed the agency in June of a data manipulation ...

Read more →

Zolgensma: a remarkable new treatment, an ICER analysis, and a poorly justified price

18 June 2019 - Defects in both sets of alleles in the coding region for the survival motor neuron 1 ...

Read more →

New cost-effectiveness methods to determine value-based prices for potential cures: what are the options?

12 June 2019 - Evaluating different approaches to assessing the clinical effectiveness and value of potential cures will be essential to ...

Read more →

ICER comments on the FDA approval of Zolgensma for the treatment of spinal muscular atrophy

24 May 2019 - ICER’s update reflects the gene therapy’s new clinical data and FDA label. ...

Read more →

Gene therapy was hailed as a revolution. Then came the bill.

7 April 2019 - Cost of new treatments may run into the millions of dollars. ...

Read more →

ICER issues final report on Spinraza and Zolgensma, provides policy recommendations related to pricing and coverage of treatments for spinal muscular atrophy

3 April 2019 - Independent appraisal committee notes family testimony in votes confirming broad benefits of both treatments; however, committee votes ...

Read more →

ICER’s assessment finds Spinraza and Zolgensma provide substantial health benefits for people with spinal muscular atrophy

22 February 2019 - Current pricing of Spinraza would require a substantial discount to meet traditional cost-effectiveness ranges; Zolgensma’s value-based price ...

Read more →

Institute for Clinical and Economic Review releases draft evidence report on treatments for spinal muscular atrophy

20 December 2018 - Public comment period now open until 31 January 2019; requests to make oral comment during public meeting ...

Read more →

Institute for Clinical and Economic Review to publish upcoming assessment on treatments for Duchenne muscular dystrophy

13 December 2018 - Report will be subject of New England CEPAC meeting in July 2019; Open Input now being accepted ...

Read more →

Novartis CEO says four factors can help with pricing and payment of life saving cell and gene therapies

26 November 2018 - The new therapies are challenging the traditional model for paying for medical treatment, and the industry is ...

Read more →